BASIC INFORMATION:
•DEFINTIONS
•EPIDEMIOLOGY
•PATHOGENESIS
•TREATMENT OPTIONS
•AFFORDABILITY
•AVAILABILITY
•PRESCRIBING TREND
COST COMPARISON OF DRUGS:
Drug Name
Price in
PAK
Price in
IND
Price in
BNG
Price in
U.K
Price in
U.A.E
Price in
U.S.A
Cyclophosphamide
0.98$
0.80$
5.98$
9.66$
4.36$
1.6$
Methotrexate
11.54$
0.81$
1.47$
4.8$
13.75$
1.6$
5 - Fluorouracil
0.65$
0.27$
0.86$
3.1$
2.81$
1.11$
Capecitabine
20.52$
1.34$
3.07$
26.55$
4.93$
2.37$
Gemicitabine
13.64$
15.06$
11.67$
32.4$
93.52$
40.76$
Cisplatin
5.70$
4.51$
7.17$
5.86$
6.53$
22.29$
Carboplatin
5.70$
10.54$
5.06$
22.86$
29.67$
126$
Vinorelbine
68.14$
65.54$
14.93$
43.98$
386$
36.20$
Paclitaxel
73.27$
7.66$
0.008$
246$
220$
15$
Docetaxel
162.81$
113$
237.72$
154.71$
1450$
116$
Doxorubicin
19.49$
10.84$
11.37$
456.13$
736.69$
213$
Epirubicin
20.35$
27.11$
34.54$
38.16$
107.81$
22.19$
Eribulin
N/A
546$
N/A
361$
907.83
1116$
Ixabepilone
N/A
407$
N/A
N/A
4656$
1146$
Tamoxifene
3.96$
4.45$
3.60$
1.62$
0.7$
0.77$
Toremifene
N/A
0.68$
N/A
0.96$
2.1$
40.5$
Fluvestrant
55.70$
1.36$
N/A
26.20$
N/A
9.81$
Letrozole
16.28$
0.37$
0.45$
3.03$
8.23$
1.07$
Exemestane
23.20$
0.58$
38$
2.96$
4.76$
2.87$
Goserelin
89.60$
391.62$
N/A
235$
262.44$
523.30$
Trastuzumab
1058.29$
290.50$
0.008$
407.40$
3359$
150$
Bevacizumab
234.45$
406.60$
239.44$
242$
627$
840$
Lapatinib
766.06$
6.03$
4.29$
11.49$
3553$
30.28$
• NOTE: ALL THE DRUG PRICES WERE FIRST FOUND IN THE RESPECTIVE CURRENCY
OF EACH COUNTRY AND THE CONVERTED INTO U.S DOLLAR ($) ACCORDING TO
THE LATEST STOCK EXCHANGE RATE. MOST EXPENSIVE MEDICINE ARE IN
PAKISTAN AND THE LEAST EXPENSIVE ARE IN INDIA.
CONVERSION RATES USED:
Currency Conversion Rates Used (10/7/18)
Currencies Converted
U.S Dollar
122.84 Pakistan Rupees
74.07 Indian Rupees
83.50 Bangladeshi Taka
3.67 United Arab Emirates Dirham
0.76 British Pound Sterling
1 U.S Dollar
REFERENCE :
1.
2.
AVAILABILITY OF ANTICANCER MEDICINES IN PUBLIC AND PRIVATE SECTORS, AND THEIR AFFORDABILITY
BY LOW, MIDDLE AND HIGHINCOME CLASS PATIENTS IN PAKISTAN MUHAMMAD REHAN SARWAR , SADIA
IFTIKHAR AND ANUM SAQIB.
MANY OTHER SOURCES.